Evidence map›Paper›PMID 41394830›Full record

ArticleFrontiers in immunology2025

Integrated multi-omics elucidates

Bing Qi, Yuwei Wu, Ning Wang, Liumeng Duan, Yangbo Wei, Xuanrui Zhang, Jing Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bing QiCollege of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China.
Yuwei WuCollege of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China.
Ning WangCollege of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China.
Liumeng DuanCollege of Basic Medical Sciences, North China University of Science and Technology, Hebei, Tangshan, China.
Yangbo WeiCollege of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China.
Xuanrui ZhangCollege of Ji Tang, North China University of Science and Technology, Tangshan, Hebei, China.
Jing ChenCollege of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an extremely poor prognosis. Gemcitabine (GEM), the standard first-line chemotherapeutic agent for PDAC, often fails due to the development of drug resistance. This study aims to systematically investigate the mechanisms underlying gemcitabine resistance in PDAC and identify novel therapeutic targets. Methods: We integrated multi-omics data, including microarray, transcriptomic, proteomic, single-cell RNA sequencing, and spatial transcriptomic datasets. Machine learning algorithms were employed to screen for key genes associated with resistance. The correlation between candidate genes and drug-resistant phenotypes was inferred using pancreatic cancer cell lines, mouse models, and clinical patient data. Functional and mechanistic studies were subsequently conducted through in vitro cellular experiments. Results: Our findings identify the prion protein gene ( Discussion: This study demonstrates that

Indexed as

Antimetabolites, AntineoplasticCarcinoma, Pancreatic DuctalDeoxycytidineDrug Resistance, NeoplasmPancreatic NeoplasmsPrion ProteinsAnimalsCell Line, TumorEpithelial-Mesenchymal TransitionGemcitabineGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMiceMultiomicsAntimetabolites, AntineoplasticDeoxycytidineGemcitabinePrion ProteinsPRNP protein, humancancer-associated fibroblastschemotherapypancreatic ductal adenocarcinomaPRNPscRNA sequencing analysis

Identifiers

PMID41394830
PMCPMC12695746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.